Genomma Lab InternacionalB de CV (MEX:LABB) 3-Year RORE % : 25.23% (As of Mar. 2026)


MEX:LABB Genomma Lab Internacional SAB de CV MEX:LABB
66 GF Score
Price MXN15.04
GF Value MXN17.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV 3-Year RORE %?

Genomma Lab InternacionalB de CV MEX:LABB +2.59% 66 3-Year RORE % is 25.23 as of Mar. 2026. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 935 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 71.98% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Genomma Lab InternacionalB de CV's 3-Year RORE % for the quarter that ended in Mar. 2026 was 25.23%.

The industry rank for Genomma Lab InternacionalB de CV's 3-Year RORE % or its related term are showing as below:

MEX:LABB's 3-Year RORE % is ranked better than
71.98% of 935 companies
in the Drug Manufacturers industry
Industry Median: 2.86 vs MEX:LABB: 25.23

Genomma Lab InternacionalB de CV  (MEX:LABB) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Genomma Lab InternacionalB de CV 3-Year RORE % Related Terms


Genomma Lab InternacionalB de CV 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV 3-Year RORE % Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.83 0.70 -17.56 12.24 27.48

Genomma Lab InternacionalB de CV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.14 -1.49 -13.03 27.48 25.23

MEX:LABB vs ZTS, UTHR, VTRS: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's 3-Year RORE % falls into.


MEX:LABB
66GF Score
Genomma Lab Internacional SAB de CV MEX:LABB
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomma Lab InternacionalB de CV 3-Year RORE % Calculation

Genomma Lab InternacionalB de CV's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 1.644-1.12 )/( 4.461-2.384 )
=0.524/2.077
=25.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 25.23 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a 3-Year RORE % of 25.23 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Genomma Lab InternacionalB de CV and its competitors. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #262 out of 935 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is Genomma Lab InternacionalB de CV's 3-Year RORE % too high?
Genomma Lab InternacionalB de CV's current 3-Year RORE % is 25.23. The Drug Manufacturers industry median 3-Year RORE % is 2.86. Genomma Lab InternacionalB de CV's value of 25.23 is 782.2% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #262 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #262 out of 935 companies for 3-Year RORE %. This puts Genomma Lab InternacionalB de CV in the upper half of its industry. The industry median 3-Year RORE % is 2.86. Genomma Lab InternacionalB de CV's value of 25.23 is 782.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 2.86, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current 3-Year RORE % of 25.23 is 782.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current 3-Year RORE % is 25.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current 3-Year RORE % is 25.23 and 782.2% above the Drug Manufacturers industry median of 2.86. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current 3-Year RORE % is 25.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for MEX:LABB:

  • 3-Year RORE %: 25.23
  • GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
  • GF Score™: 66/100 with 4 warning signs
  • Industry Position: 782.2% above the Drug Manufacturers median (#262 of 935)

No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USAGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score

Get the complete analysis for MEX:LABB

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.04
Price
MXN17.64
GF Value